Dr. Bunn Discusses Afatinib in Lung Cancer

Paul A. Bunn, Jr., MD
Published: Tuesday, Sep 17, 2013

Paul A. Bunn, Jr, MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses afatinib for patients with an activating epidermal growth factor receptor (EGFR) mutation.

Afatinib is a second-generation tyrosine kinase inhibitor that binds to the activating mutations in EGFR and has been approved by the FDA, Bunn says. There is also an EGFR mutation test that goes with the drug.

Unlike erlotinib and gefitinib, Bunn says, afatinib binds to T790M, which could lead to a longer time to resistance. Afatinib is similar to erlotinib and gefitinib in that it can cause diarrhea and skin toxicities, Bunn says.

While afatinib seems to show the same benefit as erlotinib and gefitinib, it has yet to be determined if it is actually better than those agents.
 
SELECTED
LANGUAGE
Paul A. Bunn, Jr, MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses afatinib for patients with an activating epidermal growth factor receptor (EGFR) mutation.

Afatinib is a second-generation tyrosine kinase inhibitor that binds to the activating mutations in EGFR and has been approved by the FDA, Bunn says. There is also an EGFR mutation test that goes with the drug.

Unlike erlotinib and gefitinib, Bunn says, afatinib binds to T790M, which could lead to a longer time to resistance. Afatinib is similar to erlotinib and gefitinib in that it can cause diarrhea and skin toxicities, Bunn says.

While afatinib seems to show the same benefit as erlotinib and gefitinib, it has yet to be determined if it is actually better than those agents.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication
x